KIVU-305 / Kivu Bioscience - LARVOL DELTA

Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial (Businesswire) - "Preclinical results presented at World ADC London demonstrated: Selective nanomolar binding to CEACAM5-positive tumor cells with efficient internalization; Potent target-dependent cytotoxicity and meaningful bystander killing activity....Kivu also announced another significant milestone with receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305."

First-in-human • New P1 trial • Preclinical • Solid Tumor